Log in

NASDAQ:DMPIDelMar Pharmaceuticals News Headlines

$0.92
+0.08 (+9.52 %)
(As of 05/25/2020 04:00 PM ET)
Add
Compare
Today's Range
$0.82
Now: $0.92
$0.95
50-Day Range
$0.43
MA: $0.59
$0.92
52-Week Range
$0.38
Now: $0.92
$5.75
Volume601,100 shs
Average Volume248,382 shs
Market Capitalization$10.51 million
P/E RatioN/A
Dividend YieldN/A
Beta1.43

Headlines

DelMar Pharmaceuticals (NASDAQ DMPI) News Headlines

Source:
DateHeadline
Zacks: Analysts Expect DelMar Pharmaceuticals Inc (NASDAQ:DMPI) Will Post Earnings of -$0.05 Per ShareZacks: Analysts Expect DelMar Pharmaceuticals Inc (NASDAQ:DMPI) Will Post Earnings of -$0.05 Per Share
www.americanbankingnews.com - May 19 at 4:20 AM
DMPI DelMar Pharmaceuticals, Inc. Common StockDMPI DelMar Pharmaceuticals, Inc. Common Stock
www.nasdaq.com - May 15 at 6:38 PM
DelMar Pharmaceuticals (NASDAQ:DMPI) Posts Quarterly  Earnings Results, Misses Expectations By $0.06 EPSDelMar Pharmaceuticals (NASDAQ:DMPI) Posts Quarterly Earnings Results, Misses Expectations By $0.06 EPS
www.americanbankingnews.com - May 14 at 6:50 PM
DelMar Pharmaceuticals (NASDAQ:DMPI) Receives Buy Rating from Maxim GroupDelMar Pharmaceuticals (NASDAQ:DMPI) Receives Buy Rating from Maxim Group
www.americanbankingnews.com - May 14 at 4:23 PM
DelMar Pharmaceuticals Announces Fiscal Third Quarter 2020 Financial Results and Recent Corporate UpdatesDelMar Pharmaceuticals Announces Fiscal Third Quarter 2020 Financial Results and Recent Corporate Updates
finance.yahoo.com - May 13 at 8:31 AM
Is DelMar Pharmaceuticals, Inc. (NASDAQ:DMPI) A Volatile Stock?Is DelMar Pharmaceuticals, Inc. (NASDAQ:DMPI) A Volatile Stock?
finance.yahoo.com - May 10 at 5:06 PM
BRIEF-DelMar Pharmaceuticals Provides Enrollment Update In Phase 2 Clinical Trial Of Val-083 For Adjuvant Treatment Of Brain TumorsBRIEF-DelMar Pharmaceuticals Provides Enrollment Update In Phase 2 Clinical Trial Of Val-083 For Adjuvant Treatment Of Brain Tumors
www.reuters.com - May 5 at 4:00 PM
DelMar Pharmaceuticals [Nasdaq:DMPI] Provides Enrollment Update in Phase 2 Clinical Trial of VAL-083 for Adjuvant Treatment of Brain TumorsDelMar Pharmaceuticals [Nasdaq:DMPI] Provides Enrollment Update in Phase 2 Clinical Trial of VAL-083 for Adjuvant Treatment of Brain Tumors
finance.yahoo.com - May 5 at 4:00 PM
DelMar Pharmaceuticals Receives Nasdaq Bid Price ExtensionDelMar Pharmaceuticals Receives Nasdaq Bid Price Extension
finance.yahoo.com - March 26 at 8:27 AM
BRIEF-DelMar Pharmaceuticals Reports Over 50% Enrollment In Phase 2 Clinical Trial Of VAL-083 For Adjuvant Treatment Of Brain TumorsBRIEF-DelMar Pharmaceuticals Reports Over 50% Enrollment In Phase 2 Clinical Trial Of VAL-083 For Adjuvant Treatment Of Brain Tumors
www.reuters.com - March 5 at 10:36 AM
DelMar Pharmaceuticals [Nasdaq:DMPI] Reports Over 50% Enrollment in Phase 2 Clinical Trial of VAL-083 For Adjuvant Treatment of Brain TumorsDelMar Pharmaceuticals [Nasdaq:DMPI] Reports Over 50% Enrollment in Phase 2 Clinical Trial of VAL-083 For Adjuvant Treatment of Brain Tumors
finance.yahoo.com - March 4 at 12:31 PM
BRIEF-Delmar Pharma Enrolls Final Patient In Phase 2 Clinical Trial Of Val-083 For First-Line Treatment Of Brain TumorsBRIEF-Delmar Pharma Enrolls Final Patient In Phase 2 Clinical Trial Of Val-083 For First-Line Treatment Of Brain Tumors
www.msn.com - February 19 at 1:14 PM
DelMar Pharma up 4% advancement of VAL-083 studyDelMar Pharma up 4% advancement of VAL-083 study
seekingalpha.com - February 19 at 1:14 PM
DelMar Pharmaceuticals [Nasdaq:DMPI] Enrolls Final Patient in Phase 2 Clinical Trial of VAL-083 For First-Line Treatment of Brain TumorsDelMar Pharmaceuticals [Nasdaq:DMPI] Enrolls Final Patient in Phase 2 Clinical Trial of VAL-083 For First-Line Treatment of Brain Tumors
finance.yahoo.com - February 19 at 8:13 AM
DelMar Pharmaceuticals Announces Fiscal Second Quarter 2020 Financial Results and Recent Corporate UpdatesDelMar Pharmaceuticals Announces Fiscal Second Quarter 2020 Financial Results and Recent Corporate Updates
finance.yahoo.com - February 13 at 8:30 AM
Will DelMar Pharmaceuticals (NASDAQ:DMPI) Spend Its Cash Wisely?Will DelMar Pharmaceuticals (NASDAQ:DMPI) Spend Its Cash Wisely?
finance.yahoo.com - February 10 at 1:54 PM
DelMar Pharma up 16% premarket on positive VAL-083 dataDelMar Pharma up 16% premarket on positive VAL-083 data
seekingalpha.com - January 29 at 2:19 PM
DelMar Pharmaceuticals Announces Peer-Reviewed Publication of Interim Results of Phase 2 Clinical Trial of VAL-083 As First-Line Treatment in Newly-Diagnosed MGMT-Unmethylated Glioblastoma MultiformeDelMar Pharmaceuticals Announces Peer-Reviewed Publication of Interim Results of Phase 2 Clinical Trial of VAL-083 As First-Line Treatment in Newly-Diagnosed MGMT-Unmethylated Glioblastoma Multiforme
finance.yahoo.com - January 29 at 8:05 AM
DelMar Pharmaceuticals to Present at the LD Micro 12th Annual Main Event on December 10, 2019DelMar Pharmaceuticals to Present at the LD Micro 12th Annual Main Event on December 10, 2019
finance.yahoo.com - December 3 at 12:46 PM
/C O R R E C T I O N -- DelMar Pharmaceuticals, Inc.//C O R R E C T I O N -- DelMar Pharmaceuticals, Inc./
finance.yahoo.com - November 25 at 2:14 PM
DelMar Pharmaceuticals Announces Fiscal First Quarter 2020 Financial Results and Recent Corporate UpdatesDelMar Pharmaceuticals Announces Fiscal First Quarter 2020 Financial Results and Recent Corporate Updates
finance.yahoo.com - November 14 at 8:19 AM
Before You Buy DelMar Pharmaceuticals, Inc. (NASDAQ:DMPI), Consider Its VolatilityBefore You Buy DelMar Pharmaceuticals, Inc. (NASDAQ:DMPI), Consider Its Volatility
finance.yahoo.com - November 11 at 2:13 PM
DelMar Pharmaceuticals to Host Key Opinion Leader Summit on Glioblastoma Multiforme and the Potential for Treatment with VAL-083DelMar Pharmaceuticals to Host Key Opinion Leader Summit on Glioblastoma Multiforme and the Potential for Treatment with VAL-083
finance.yahoo.com - November 5 at 12:35 PM
DelMar Pharmaceuticals to Present Updates of Two Phase 2 Clinical Trials of VAL-083 at the 2019 Society for NeuroOncology Annual MeetingDelMar Pharmaceuticals to Present Updates of Two Phase 2 Clinical Trials of VAL-083 at the 2019 Society for NeuroOncology Annual Meeting
finance.yahoo.com - October 29 at 1:28 PM
DelMar Pharmaceuticals to Present on October 29th at the 5th Annual Dawson James Small Cap Growth ConferenceDelMar Pharmaceuticals to Present on October 29th at the 5th Annual Dawson James Small Cap Growth Conference
finance.yahoo.com - October 24 at 12:41 PM
DelMar Pharmaceuticals (DMPI) Presents At MicroCap Rodeo Investor Conference - SlideshowDelMar Pharmaceuticals (DMPI) Presents At MicroCap Rodeo Investor Conference - Slideshow
seekingalpha.com - October 17 at 5:57 PM
DelMar Pharmaceuticals to Present at the Inaugural MicroCap Rodeo Investor Conference on October 15, 2019 at 11:30 AM Central TimeDelMar Pharmaceuticals to Present at the Inaugural MicroCap Rodeo Investor Conference on October 15, 2019 at 11:30 AM Central Time
finance.yahoo.com - October 10 at 9:08 AM
DelMar Pharmaceuticals to Present at the Fall Investor Summit on September 16, 2019DelMar Pharmaceuticals to Present at the Fall Investor Summit on September 16, 2019
finance.yahoo.com - September 12 at 1:20 PM
DelMar Pharmaceuticals Announces Fiscal Year 2019 Financial Results and Recent Corporate UpdatesDelMar Pharmaceuticals Announces Fiscal Year 2019 Financial Results and Recent Corporate Updates
finance.yahoo.com - September 11 at 5:56 AM
DelMar regains Nasdaq listing complianceDelMar regains Nasdaq listing compliance
seekingalpha.com - September 9 at 12:57 PM
DelMar Pharmaceuticals Reports Full Compliance with Nasdaq Listing CriteriaDelMar Pharmaceuticals Reports Full Compliance with Nasdaq Listing Criteria
finance.yahoo.com - September 9 at 12:56 PM
DelMar Pharmaceuticals Relocates Headquarters to San Diego, CaliforniaDelMar Pharmaceuticals Relocates Headquarters to San Diego, California
finance.yahoo.com - September 4 at 8:46 AM
12 Healthcare Stocks Moving In Tuesdays Pre-Market Session12 Healthcare Stocks Moving In Tuesday's Pre-Market Session
www.msn.com - August 27 at 10:19 PM
DelMar Pharma down 12% after trial updateDelMar Pharma down 12% after trial update
seekingalpha.com - August 27 at 10:19 PM
DelMar Pharma down 35% premarket ahead of equity offering pricingDelMar Pharma down 35% premarket ahead of equity offering pricing
seekingalpha.com - August 14 at 11:13 PM
DelMar Pharmaceuticals Announces Pricing Of $6.8 Million Underwritten Public OfferingDelMar Pharmaceuticals Announces Pricing Of $6.8 Million Underwritten Public Offering
finance.yahoo.com - August 14 at 11:13 PM
DelMar Pharma up 5% on positive VAL-083 dataDelMar Pharma up 5% on positive VAL-083 data
seekingalpha.com - August 14 at 12:17 AM
DelMar Pharmaceuticals Reports Updated Results on Twenty Patients from the Phase 2 Clinical Trial of VAL-083 as First-Line Treatment in Newly-Diagnosed MGMT-Unmethylated Glioblastoma MultiForme (GBM)DelMar Pharmaceuticals Reports Updated Results on Twenty Patients from the Phase 2 Clinical Trial of VAL-083 as First-Line Treatment in Newly-Diagnosed MGMT-Unmethylated Glioblastoma MultiForme (GBM)
finance.yahoo.com - August 14 at 12:16 AM
DelMar Pharma to offer nearly 5M sharesDelMar Pharma to offer nearly 5M shares
seekingalpha.com - August 13 at 5:56 AM
DelMar Pharma up 43% on advancement of VAL-083DelMar Pharma up 43% on advancement of VAL-083
seekingalpha.com - August 1 at 12:37 AM
DelMar Pharmaceuticals Achieves Two-Thirds Enrollment for Phase 2 Clinical Trial of VAL-083 As First-Line Treatment in Newly-Diagnosed MGMT-Unmethylated Glioblastoma MultiForme (GBM)DelMar Pharmaceuticals Achieves Two-Thirds Enrollment for Phase 2 Clinical Trial of VAL-083 As First-Line Treatment in Newly-Diagnosed MGMT-Unmethylated Glioblastoma MultiForme (GBM)
finance.yahoo.com - July 31 at 8:15 AM
DelMar Pharmaceuticals Enrolls First Patient in the Recently-Approved Adjuvant Setting Arm of Phase 2 Study of VAL-083 for the Treatment of MGMT-Unmethylated Glioblastoma MultiformeDelMar Pharmaceuticals Enrolls First Patient in the Recently-Approved Adjuvant Setting Arm of Phase 2 Study of VAL-083 for the Treatment of MGMT-Unmethylated Glioblastoma Multiforme
finance.yahoo.com - July 25 at 12:14 AM
Here Is Whats Driving The Rally In DelMar PharmaceuticalsHere Is What's Driving The Rally In DelMar Pharmaceuticals
finance.yahoo.com - July 25 at 12:14 AM
DelMar Announces Relocation of Company Headquarters to San DiegoDelMar Announces Relocation of Company Headquarters to San Diego
finance.yahoo.com - July 22 at 8:10 PM
DelMar to relocate headquarters to San DiegoDelMar to relocate headquarters to San Diego
seekingalpha.com - July 10 at 7:14 PM
Delmar Pharmaceuticals terminates rights offeringDelmar Pharmaceuticals terminates rights offering
seekingalpha.com - June 27 at 8:04 AM
DelMar Pharma extends rights offering to July 12DelMar Pharma extends rights offering to July 12
seekingalpha.com - June 26 at 8:03 AM
DelMar Pharmaceuticals Announces Closing of FinancingDelMar Pharmaceuticals Announces Closing of Financing
finance.yahoo.com - June 21 at 8:01 PM
Delmar Pharmaceuticals Updates The Terms Of Previously Announced Rights OfferingDelmar Pharmaceuticals Updates The Terms Of Previously Announced Rights Offering
finance.yahoo.com - June 21 at 8:01 PM
Delmar Pharma updates terms of rights offeringDelmar Pharma updates terms of rights offering
seekingalpha.com - June 11 at 8:04 AM
This page was last updated on 5/25/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.